Akamis Bio
Akamis Bio is a clinical-stage oncology company dedicated to leveraging its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. The company develops a portfolio of solid tumor-targeted T-SIGn® therapeutics designed to enable the immune system to recognize, attack, and clear cancer, with a focus on innovative viral vector-based gene therapies. Their mission is to turn cancer cells into 'drug factories' to trigger robust antitumor immune responses, aiming to improve outcomes for patients with difficult-to-treat solid tumors.
Industries
Nr. of Employees
medium (51-250)
Akamis Bio
245 Main St 2nd floor, Cambridge, MA 02142, United States
Patents
Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
US-12049513-B2
View Details
Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
US-12049513-B2
View DetailsProducts
NG-350A
Intravenously delivered tumor-selective vector engineered to express a secreted CD40 agonist antibody intratumorally to activate antigen-presenting cells and recruit T cells.
NG-641
Intravenously delivered tumor-selective vector encoding a FAP-directed bispecific T-cell activator and immune-enhancer payloads (including chemokines and interferon alpha) to recruit T cells and modulate tumor stroma.
NG-348
Tumor-selective vector designed to express membrane-bound CD80 and an anti-CD3 single-chain engager to directly engage and activate T cells within the tumor.
NG-7XX (discovery series)
Concept-stage vectors designed to deliver multiple transgenes such as IL-12, IL-15 and chemokines to activate T-cell and NK-cell responses within tumors.
Additional research-stage tumor-targeting vectors
Undisclosed and concept-stage vectors focused on delivering synthetic or natural tumor antigens, CAR-T targeting constructs, and other payload packages tailored to solid tumor types.
NG-350A
Intravenously delivered tumor-selective vector engineered to express a secreted CD40 agonist antibody intratumorally to activate antigen-presenting cells and recruit T cells.
NG-641
Intravenously delivered tumor-selective vector encoding a FAP-directed bispecific T-cell activator and immune-enhancer payloads (including chemokines and interferon alpha) to recruit T cells and modulate tumor stroma.
NG-348
Tumor-selective vector designed to express membrane-bound CD80 and an anti-CD3 single-chain engager to directly engage and activate T cells within the tumor.
NG-7XX (discovery series)
Concept-stage vectors designed to deliver multiple transgenes such as IL-12, IL-15 and chemokines to activate T-cell and NK-cell responses within tumors.
Additional research-stage tumor-targeting vectors
Undisclosed and concept-stage vectors focused on delivering synthetic or natural tumor antigens, CAR-T targeting constructs, and other payload packages tailored to solid tumor types.
Services
Co-development and research collaborations with academic, research institute and biopharma partners to evaluate novel payloads and combination regimens.
Design and conduct of early-phase clinical studies (Phase 1/1a/1b) evaluating safety, tolerability, pharmacodynamics and preliminary efficacy of systemically dosed tumor gene therapies.
Measurement and analysis of translational markers including viral replication, transgene expression, cytokine responses and tumor microenvironment remodeling to support mechanism-of-action evaluations.
Co-development and research collaborations with academic, research institute and biopharma partners to evaluate novel payloads and combination regimens.
Design and conduct of early-phase clinical studies (Phase 1/1a/1b) evaluating safety, tolerability, pharmacodynamics and preliminary efficacy of systemically dosed tumor gene therapies.
Measurement and analysis of translational markers including viral replication, transgene expression, cytokine responses and tumor microenvironment remodeling to support mechanism-of-action evaluations.
Expertise Areas
- Tumor-targeted viral vector development
- Immuno-oncology therapeutic development
- Preclinical tumor model evaluation and translational research
- Early-phase clinical trial design and execution
Key Technologies
- Adenoviral vector-based gene delivery
- Systemic (intravenous) tumor-homing viral vectors
- Directed evolution for vector tropism
- Multi-transgene payload engineering